Amantadine in the Treatment of Neuroendocrine Side Effects of Neuroleptics

Correa, Nereida; Opler, Lewis A.; Kay, Stanley R.; Birmaher, Boris

doi:10.1097/00004714-198704000-00008

Cited by 72 publications

(46 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…All of them were short-term and had small sample sizes, as shown in Table 1. [13][14][15][16][17][18][19][20][21][22][23][24][25] Bromocriptine was involved in the treatment of these dysfunctions in two studies, sildenafi l in four, amantadine in two and cyproheptadine, imipramine, shakuyaku-kanzo-to, cabergoline and selegiline in one each.…”

Section: Resultsmentioning

confidence: 99%

“…30 A description of the main drugs, respective doses, potential drug interactions and side effects can be found in Table 2. [13][14][15][16][17][18][19][20]23,24,27,[30][31][32][33][34][35][36][37][38] DISCUSSION Sexual performance among patients with schizophrenia may differ from the qualitative and quantitative patterns in the normal population. It may be altered through three main factors: by the disease itself as a consequence of affective and/or cognitive impairment; by antipsychotic drugs; and by other clinical problems (such as diabetes, hypertension, alcohol and drug abuse).…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

A systematic review on clinical management of antipsychotic-induced sexual dysfunction in schizophrenia

2006

View full text Add to dashboard Cite

INTRODUCTION: Sexual dysfunction frequently occurs in patients with schizophrenia under antipsychotic therapy, and the presence of sexual side effects may affect compliance. The aim of this study was to review and describe clinical findings relating to the appropriate management of such dysfunctions. MATERIAL AND METHODS: The research was carried out through Medline (from 1966 to March 2005), PsycInfo (from 1974 to March 2005), and Cochrane Library (from 1965 to March 2005) and included any kind of study, from case reports to randomized trials. RESULTS: The most common sexual dysfunctions found in the literature were libido decrease, difficulties in achieving and maintaining erection, ejaculatory dysfunction, orgasmic dysfunction, and menstrual irregularities. Thirteen papers were found: eight of them were open-label studies, four were descriptions of cases, and only one was a randomized clinical trial. All of them were short-term and had small sample sizes. The agents used were: bromocriptine, cabergoline, cyproheptadine, amantadine, shakuyaku-kanzo-to, sildenafil and selegiline. DISCUSSION: There was no evidence that those agents had proper efficacy in treating the antipsychotic-induced sexual dysfunction. An algorithm for managing sexual dysfunction induced by antipsychotics is suggested as a support for clinical decisions. Since the outcome from schizophrenia treatment is strongly related to compliance with the antipsychotics, prevention of sexual dysfunction is better than its treatment, since there is a scarcity of data available regarding the efficacy of intervention to deal with these problems.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

A systematic review on clinical management of antipsychotic-induced sexual dysfunction in schizophrenia

2006

View full text Add to dashboard Cite

show abstract

“…In contrast, no effect of metformine was reported in five patients on long-term treatment with haloperidol, fluphenazine, trifluperazine or risperidone (Baptista et al 2001). Weight reduction was reported with open-label add-on treatment of amantadine after 2 weeks in 10 patients taking FGAs (Correa et al 1987). The effect of weight loss could be confirmed by add-on treatment with 100 Á/300 mg/day amantadine for 3Á/6 months in 12 patients who gained excessive weight while taking olanzapine (Floris et al 2001), and in a double-blind, 16-week trial in 60 patients with schizophrenia, schizophreniform or bipolar disorder compared to placebo (Deberdt et al 2005).…”

Section: Obesity and Weight Gainmentioning

confidence: 90%

World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, Part 2: Long-term treatment of schizophrenia

Falkai

Wobrock

Lieberman

et al. 2006

The World Journal of Biological Psychiatry

201

View full text Add to dashboard Cite

These guidelines for the biological treatment of schizophrenia were developed by an international Task Force of the World Federation of Societies of Biological Psychiatry (WFSBP). The goal during the development of these guidelines was to review systematically all available evidence pertaining to the treatment of schizophrenia, and to reach a consensus on a series of practice recommendations that are clinically and scientifically meaningful based on the available evidence. These guidelines are intended for use by all physicians seeing and treating people with schizophrenia. The data used for developing these guidelines have been extracted primarily from various national treatment guidelines and panels for schizophrenia, as well as from meta-analyses, reviews and randomised clinical trials on the efficacy of pharmacological and other biological treatment interventions identified by a search of the MEDLINE database and Cochrane Library. The identified literature was evaluated with respect to the strength of evidence for its efficacy and then categorised into four levels of evidence (A Á/D). This second part of the guidelines covers the long-term treatment as well as the management of relevant side effects. These guidelines are primarily concerned with the biological treatment (including antipsychotic medication, other pharmacological treatment options, electroconvulsive therapy, adjunctive and novel therapeutic strategies) of adults suffering from schizophrenia.Key words: Schizophrenia, long-term treatment, evidence-based medicine, practice guidelines, biological treatment, antipsychotics EXECUTIVE SUMMARY OF RECOMMENDATIONS General recommendationsSpecific treatment strategies are required not only for patients suffering from acute schizophrenia, but also in the stabilisation and stable phase of the disease. The stabilisation period follows the acute phase and constitutes a time-limited transition to continuing treatment in the stable phase. The stable phase represents a prolonged period of treatment and rehabilitation during which symptoms are under adequate control and the focus is on improving functioning and recovery. The goals of long-term therapy have to be discussed with the patient on the background of adequately provided information and his personal goals in order to find common ground to encourage a long-term medication strategy (shared-decision making). In this regard a treatment plan must be formulated and implemented. During the stabilisation phase, the main goals of treatment are to facilitate continued reduction in symptoms, consolidate remission, and promote the process of recovery. The main goals of treatment during the stable phase are to ensure that symptom remission or control is sustained, that the patient is maintaining or improving the level of functioning and quality of life, to prevent relapse, and to ensure that monitoring for adverse treatment effects continues. The antipsychotic pharmacological therapy should be accompanied by psychosocial interventions. A number of psychosocial...

show abstract

“…1987(Baptista er al. & 1990Bernstein 1992;Parada et al 1988), and an endocrine effect related to the drug-induced hyperprolactinaemia (Baptista et al 1997(Baptista et al a & d, 1998Correa et a/. 1987;Parada et al 1989).…”

mentioning

confidence: 99%

Glucose Tolerance and Serum Insulin Levels in an Animal Model of Obesity Induced by the Antipsychotic Drug, Sulpiride

Baptista

Lacruz

Hernández

1998

Pharmacology & Toxicology

View full text Add to dashboard Cite

Ahsfruct:To assess the role of insulin in the development of obesity induced by antipsychotic drugs, a glucose tolerance test was conducted in 40 female rats during the peak of sulpiride-induced weight gain and in 40 vehicle-treated animals. The glucose area under the curve did not differ between the groups (P=0.24), however, the area under the insulin curve was significantly decreased by sulpiride (55.252.8 versus 115.6t 18.9, P=0.007). The results suggest that insulin resistance and hyperinsulinaemia are not involved in the excessive weight gain observed in this animal model of drug-induced obesity.

show abstract

Amantadine in the Treatment of Neuroendocrine Side Effects of Neuroleptics

Cited by 72 publications

References 0 publications

A systematic review on clinical management of antipsychotic-induced sexual dysfunction in schizophrenia

A systematic review on clinical management of antipsychotic-induced sexual dysfunction in schizophrenia

World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, Part 2: Long-term treatment of schizophrenia

Glucose Tolerance and Serum Insulin Levels in an Animal Model of Obesity Induced by the Antipsychotic Drug, Sulpiride

Contact Info

Product

Resources

About